Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation

Area of Science:

• Oncology
• Genomics
• Health Services Research

Background:

• Cancer treatment is shifting towards precision medicine, utilizing tumor-agnostic therapies based on molecular characteristics rather than tumor origin.
• The US Food and Drug Administration's 2017 approval of pembrolizumab marked a turning point, leading to nine approved tumor-agnostic drugs that benefit patients with rare cancers and actionable genomic alterations.

Purpose of the Study:

• To review the global landscape of tumor-agnostic drug approvals, regulatory pathways, and implementation.
• To identify barriers to access across regulatory, reimbursement, infrastructure, and workforce domains.
• To propose a framework for equitable implementation of these advanced therapies.

Main Methods:

• A comprehensive review of tumor-agnostic drug approvals and implementation experiences across Europe, Asia-Pacific, Latin America, Africa, and the Middle East.
• Analysis of barriers to access, including regulatory hurdles, reimbursement issues, infrastructure limitations, and workforce shortages.
• Development of a conceptual framework for equitable implementation based on identified challenges.

Main Results:

• Access to tumor-agnostic therapies is inconsistent globally, with less than 50% of eligible patients receiving matched treatments even in high-resource settings.
• Europe faces fragmented national reimbursement decisions despite centralized regulatory approval, causing access delays.
• Asia-Pacific shows growth but struggles with urban-rural disparities, while Latin America, Africa, and the Middle East face fundamental infrastructure and workforce barriers.

Conclusions:

• Equitable implementation requires a four-pillar framework: comprehensive biomarker testing, innovative clinical trials, harmonized regulatory and reimbursement mechanisms, and investment in a genomically competent workforce.
• International initiatives like Project Orbis show promise for regulatory convergence.
• Coordinated global strategies are essential to bridge the gap between genomic innovation and geographic accessibility, ensuring all patients benefit from tumor-agnostic therapies.